Treatment of Mycobacterium abscessus disease is highly complex. For this highly drug-resistant mycobacterium very few active antibiotics exist and those few drugs are highly toxic and not universally available or affordable.

These factors, combined with individual experiences and preferences, impact on the selection of antibiotics for the first -or intensive-  phase of antibiotic treatment.

To study these preferences, we invite you to participate in an NTM-net survey study.

Our request to you: participate in a 7-minute survey of case-based treatment decisions

Target group: physicians with experience treating M. abscessus disease (no limits on amount of experience)

We hope you will join the survey so we can better understand differences in treatment approaches.